Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.